These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 31399508)

  • 41. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
    Jacqueroux E; Hodin S; Saib S; He Z; Bin V; Delézay O; Delavenne X
    Eur J Pharm Biopharm; 2020 Mar; 148():27-37. PubMed ID: 31945490
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro.
    Tsakalozou E; Adane ED; Kuo KL; Daily A; Moscow JA; Leggas M
    Drug Metab Dispos; 2013 Jul; 41(7):1404-13. PubMed ID: 23620484
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rhinacanthin-C enhances doxorubicin cytotoxicity via inhibiting the functions of P-glycoprotein and MRP2 in breast cancer cells.
    Chaisit T; Siripong P; Jianmongkol S
    Eur J Pharmacol; 2017 Jan; 795():50-57. PubMed ID: 27916559
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions.
    Zhang Q; Zhang Y; Boer J; Shi JG; Hu P; Diamond S; Yeleswaram S
    Drug Metab Dispos; 2017 Jun; 45(6):612-623. PubMed ID: 28283500
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
    Chen X; Unadkat JD; Mao Q
    Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interplay of drug transporters P-glycoprotein (MDR1), MRP1, OATP1A2 and OATP1B3 in passage of maraviroc across human placenta.
    Tupova L; Hirschmugl B; Sucha S; Pilarova V; Székely V; Bakos É; Novakova L; Özvegy-Laczka C; Wadsack C; Ceckova M
    Biomed Pharmacother; 2020 Sep; 129():110506. PubMed ID: 32768979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synergy between rhinacanthins from Rhinacanthus nasutus in inhibition against mosquito cytochrome P450 enzymes.
    Kotewong R; Pouyfung P; Duangkaew P; Prasopthum A; Rongnoparut P
    Parasitol Res; 2015 Jul; 114(7):2567-79. PubMed ID: 25869958
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    Bleasby K; Fillgrove KL; Houle R; Lu B; Palamanda J; Newton DJ; Lin M; Chan GH; Sanchez RI
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of
    Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
    Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
    Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y
    Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro.
    Rickert V; Haefeli WE; Weiss J
    Pulm Pharmacol Ther; 2014 Aug; 28(2):130-7. PubMed ID: 24657506
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ochratoxin A transport by the human breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), and organic anion-transporting polypeptides 1A2, 1B1 and 2B1.
    Qi X; Wagenaar E; Xu W; Huang K; Schinkel AH
    Toxicol Appl Pharmacol; 2017 Aug; 329():18-25. PubMed ID: 28532671
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
    Guo A; Marinaro W; Hu P; Sinko PJ
    Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Effects of Drug Metabolizing Enzyme Inhibitors on Hepatic Efflux and Uptake Transporters.
    Cheong J; Halladay JS; Plise E; Sodhi JK; Salphati L
    Drug Metab Lett; 2017; 11(2):111-118. PubMed ID: 29032766
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport.
    Pahwa S; Alam K; Crowe A; Farasyn T; Neuhoff S; Hatley O; Ding K; Yue W
    J Pharm Sci; 2017 Aug; 106(8):2123-2135. PubMed ID: 28373111
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
    Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
    Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
    Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
    Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of the Clinical Drug-Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach.
    de Vries M; Bonsmann S; Pausch J; Sumner M; Birkmann A; Zimmermann H; Kropeit D
    Clin Pharmacol Drug Dev; 2024 Jul; 13(7):755-769. PubMed ID: 38752475
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of drug-drug interaction for silymarin.
    Doehmer J; Tewes B; Klein KU; Gritzko K; Muschick H; Mengs U
    Toxicol In Vitro; 2008 Apr; 22(3):610-7. PubMed ID: 18249085
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preliminary
    Reinoso RF; Yeste S; Ayet E; Pretel MJ; Balada A; Serafini MT
    Xenobiotica; 2021 Apr; 51(4):373-386. PubMed ID: 33350877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.